Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8519316 | 0.80 | TSHR (0.48) | KDM4ETSHRKMT2ACYP19A1 | |
| SCHEMBL8676416 | 0.80 | TSHR (0.48) | KDM4ETSHRKMT2ACYP19A1 | |
| SCHEMBL4298893 | 0.80 | TSHR (0.48) | KDM4ETSHRKMT2ACYP19A1 | |
| SCHEMBL16321194 | 0.78 | CYP2A6 (0.43) | CYP11B2CYP2A6CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL16321193 | 0.78 | CYP2A6 (0.43) | CYP11B2CYP2A6CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL28585101 | 0.74 | CYP2A6 (0.49) | CYP11B2CYP2A6KDM4ECYP3A4THRB | |
| SCHEMBL18301367 | 0.74 | CYP2A6 (0.49) | CYP11B2CYP2A6KDM4ECYP3A4THRB | |
| SCHEMBL1444921 | 0.74 | — | — | |
| SCHEMBL4672270 | 0.74 | — | — | |
| SCHEMBL4478683 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890139-B2 | CYP17 inhibitors/antiandrogens | ORION CORPORATION (FI) | 2018-02-13 | — | — | US | disclosed |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2016-05-12 | — | — | US | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124882-A1 | NOVEL PIPERIDINYL-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | CYP17A1, CYP19A1, CYP21A2 | CYP11B2 9/4885CYP2A6 66/4885KDM4E 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.